The Cosmc connection to the Tn antigen in cancer
Open accessThe DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
Abstract
The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAcα1-O-Ser/Thr (Tn antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide α-N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Galβ1-3GalNAcα1-O-Ser/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 β3-galactosyltransferase or C1GalT). Formation of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by Cosmc on the X-chromosome (Xq24 in humans, Xc3 in mice). Cosmc resides in the endoplasmic reticulum (ER) and prevents misfolding, aggregation, and proteasome-dependent degradation of newly synthesized T-synthase. Loss of expression of active T-synthase or Cosmc can lead to expression of the Tn antigen, along with its sialylated version Sialyl Tn antigen as observed in several cancers. Both genetic and epigenetic pathways, in addition to potential metabolic regulation, can result in abnormal expression of the Tn antigen. Engineered expression of the Tn antigen by disruption of either C1GalT (T-syn) or Cosmc in mice is associated with a tremendous range of pathologies and engineered expression of the Tn antigen in mouse embryos leads to embryonic death. Studies indicate that many membrane glycoproteins expressing the Tn antigen and/or truncated O-glycans may be dysfunctional, due to degradation and/or misfolding. Thus, expression of normal O-glycans is associated with health and homeostasis whereas truncation of O-glycans, e.g. the Tn and/or Sialyl Tn antigens is associated with cancer and other pathologies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“have been noted as hallmarks of cancer [6], it is of-”
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679 · cited 1×
“in the United States and worldwide [1,2], despite de-”
Glycosylation in Cellular Mechanisms of Health and Disease
Ohtsubo, K., & Marth, J. D. (2006) · Cell · doi:10.1016/j.cell.2006.08.019 · Cited by 2,788
Intra-tumour heterogeneity: a looking glass for cancer?
Marusyk, A., Almendro, V., & Polyak, K. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3261 · Cited by 2,000
Mucins in cancer: protection and control of the cell surface
Hollingsworth, M. A., & Swanson, B. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1251 · Cited by 1,807 · cited 1×
“pression of some mucins is associated with the tumor phenotype [16,121,122].”
Van der Sluis, M., De Koning, B. A. E., De Bruijn, A. C. J. M., Velcich, A., Meijerink, J. P. P., Van Goudoever, J. B., Büller, H. A., Dekker, J., Van Seuningen, I., Renes, I. B., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.020 · Cited by 1,684 · cited 1×
“Among the GI tract mucins, MUC2, which is mainly synthesized and secreted by the goblet cells, is an important mucus layer component to protect epithelial cells [123].”
The urokinase-type plasminogen activator system in cancer metastasis: A review
Andreasen, P. A., Kjøller, L., Christensen, L., & Duffy, M. J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970703)72:1<119::aid-ijc17>3.0.co;2-e · Cited by 1,552 · cited 1×
“One of the most useful mouse anti-Tn mAb is an IgM (CA3638, clone 12A8-C7-F5), one of several clones originally developed by Springer and colleagues, and useful in IHC and flow cytometry to detect the Tn antigen [171].”
T and Tn, General Carcinoma Autoantigens
Springer, G. F. (1984) · Science · doi:10.1126/science.6729450 · Cited by 1,009 · cited 1×
“Springer’s group developed specific monoclonal antibodies (mAbs) to the Tn antigen [98] and found that the Tn antigen was commonly expressed in many tumor cells [22].”
Colorectal Cancer in Mice Genetically Deficient in the Mucin Muc2
Velcich, A., Yang, W., Heyer, J., Fragale, A., Nicholas, C., Viani, S., Kucherlapati, R., Lipkin, M., Yang, K., & Augenlicht, L. (2002) · Science · doi:10.1126/science.1069094 · Cited by 936 · cited 1×
“MUC2 -deficient ( MUC2 − / − ) mice develop small and large intestinal and rectal tumors, indicating that loss of MUC2 could be an initiating event in intestinal tumorigenesis [124].”
Bennett, E. P., Mandel, U., Clausen, H., Gerken, T. A., Fritz, T. A., & Tabak, L. A. (2012) · Glycobiology · doi:10.1093/glycob/cwr182 · Cited by 876 · cited 2×
“A large set of approximately 20 different ppGalNAcTs, most of which have a catalytic domain and a separate lectin domain that binds the product of the reaction, leads to efficient modi-fication of specific Ser/Thr residues [43,47].”
Research works printed but not linked: 2
- [84]Ju T Otto VI Cummings RD The Tn antigen-structural simplicity and biological complexity Angew Chem Int Ed Engl 2011 50 8 1770 91 21259410 PMC7159538
- [87]Friedenreich V The Thomsen Hemagglutination Phenomenon: Production of a Specific Receptor Quality in Red Corpuscles by Bacterial Activity Dissertation Thesis Copenhagen Levin and Munksgaard 1930
Cited by
Items 101–153 of 153
Oshi, M., Ziazadeh, D., Wu, R., Chida, K., Yamada, A., Yamamoto, S., Narui, K., Li, Y., Ishikawa, T., Endo, I., et al. (2023) · Cancers · doi:10.3390/cancers15133489 · Cited by 8
“The Tn antigen, well-recognized in its role in cancer progression, has been implicated in stimulating cell adhesion, driving cell migration and invasion, and promoting the formation of metastases [19].”
BackgroundExploring Photoredox Catalytic Reactions as an Entry to Glycosyl-α-amino Acids
Bretón, C., Oroz, P., Torres, M. R., Zurbano, M. M., García‐Orduña, P., Avenoza, A., Busto, J. H., Corzana, F., & Peregrina, J. M. (2024) · ACS Omega · doi:10.1021/acsomega.4c07412 · Cited by 12
Khiaowichit, J., Talabnin, C., Dechsukhum, C., Silsirivanit, A., & Talabnin, K. (2022) · Life · doi:10.3390/life12020174 · Cited by 11
Persson, N., Jansson, B., Stuhr‐Hansen, N., Kovács, A., Welinder, C., Danielsson, L., & Blixt, O. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168761 · Cited by 8
Morticelli, L., Magdei, M., Tschalaki, N., Petersen, B., Haverich, A., & Hilfiker, A. (2021) · Xenotransplantation · doi:10.1111/xen.12705 · Cited by 7
Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment
Zhao, S., Fu, C., Gong, B., Wu, H., Zhang, R., Cai, H., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1660852 · Cited by 11
The cytokine-cosmc signaling axis upregulates the tumor-associated carbohydrate antigen Tn
Ho, C.-W., Lin, C., Liaw, Y.-W., Chiang, H., Chin, Y., Huang, R., Lai, H., Hsu, Y., Kuo, P., Chen, C.-E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11324 · Cited by 7
Tn antigen promotes breast cancer metastasis via impairment of CASC4
Li, R., Dong, X., Chen, S., Tan, J.-Y. B., Chen, X., Liu, J., Wen, T., & Ru, X. (2023) · Cell Biology International · doi:10.1002/cbin.12077 · Cited by 7
Dwivedi, V., Saini, P., Tasneem, A., Agarwal, K., & Sampathkumar, S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.08.131 · Cited by 7
Liu, J., Xu, F., Li, J., & Jiang, H. (2020) · Bioscience Reports · doi:10.1042/bsr20191062 · Cited by 7
RetractedAnandakrishnan, R., Zyvoloski, I. J., Zyvoloski, L. R., Opoku, N. K., Dai, A., & Antony, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-40256-9 · Cited by 7
Overexpression of Tn antigen induces chronic pancreatitis in mice
Mercanoglu, B., Schraps, N., Giannou, A. D., Neuburg, E., Kempski, J., Wagener, C., Melling, N., Bockhorn, M., Hackert, T., & Wolters‐Eisfeld, G. (2025) · Scientific Reports · doi:10.1038/s41598-025-96060-0 · Cited by 5
“In this study, we evaluated the impact of the overexpression of the Tn antigen, a common precursor of O - glycans 18 , in a transgenic mouse model.”
Groux‐Degroote, S., Foulquier, F., Cavdarli, S., & Delannoy, P. (2021) · médecine/sciences · doi:10.1051/medsci/2021082 · Cited by 11
Chen, J., Yin, Z., Song, W., He, B., & Zhang, W. (2022) · Journal of Immunology Research · doi:10.1155/2022/2931214 · Cited by 6
“MKN45 SC cells and AGS SC cells are derived from two gastric cancer cell lines, MKN45 and AGS, by knocking out the COSMC gene, which is essential for O-glycan elongation [47, 48].”
BackgroundVerhassel, A., Kimani, M., Gidwani, K., Sandholm, J. A., Gawlitza, K., Rurack, K., & Härkönen, P. L. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2405454 · Cited by 4
“Ther efor e, the Tn-antigen could act as a marker for various cancers, particularly at their early stages, and could thus be applied in early cancer diagnosis [ 14 , 15 ].”
BackgroundMethodInfluentialTn as a potential predictor for regional lymph node metastasis in T1 colorectal cancer
Kuo, L., Fang, C., Su, R., Lin, Y., Wei, P., Kung, C., & Chen, C. (2023) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2023.04.112 · Cited by 4
The clinical role of glycobiology on ovarian cancer progression
Armbrister, R., Ochoa, L., & Abbott, K. L. (2022) · Advances in cancer research · doi:10.1016/bs.acr.2022.07.004 · Cited by 6
Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?
Segatori, V. I., Ferreira, G. M., Rojo, S., Nogueira, A. C., Castillo, J. O., Gulino, C. A., & Gabri, M. R. (2023) · Immuno · doi:10.3390/immuno3020009 · Cited by 5
Expression and in vitro glycosylation of recombinant edible bird nest (EBN) mucin
Cheng, G., Lyu, Y.-S., Ran, R., Liu, L., & Voglmeir, J. (2023) · Food Materials Research · doi:10.48130/fmr-0023-0037 · Cited by 3
Ranjbary, A. G., Mehrzad, J., Rahbar, N., & Dehghani, H. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08766-x · Cited by 3
Correlation of Tn antigen expression with mucins in Chinese patients with colorectal cancer.
Jiang, Y., Liu, Z., Hu, Y., Gao, T., Wen, T., & An, G. (2018) · PubMed Central · Cited by 3
Complex Glycans and Immune Regulation
Paschall, A. V., Middleton, D. R., & Avci, F. Y. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00004-3 · Cited by 3
Sialic Acids: Structural Diversity, Biological Roles, and Advances in Analytical Techniques
Faraji, M., Yaghoobpour, T., Faraji, M., & Nazıfı, S. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2508868 · Cited by 4
“[55] A key feature of tumor progression is the upregulation of terminal sialylation, which reduces adhesion to the extracellular matrix and masks cancer cells from immune detection.”
Aghamiri, S. S., & Amin, R. (2024) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases2040025 · Cited by 2
“When Cosmc is defective or its expression is downregulated, similar to C1GALT1 [49], it results in defect O-glycans motifs, including the exposure of Tn (Figure 6A), and sialyl-Tn antigens (STn), well-known cancer-associated carbohydrate antigens [50].”
Durin, Z., Layotte, A., Morelle, W., Houdou, M., Folcher, A., Legrand, D., Lefeber, D. J., Prevarskaya, N. B., von Blume, J., Cormier‐Daire, V., et al. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05551-2 · Cited by 2
Tn Hitchhiker Vaccines for High-Affinity Antibody Production and Targeted Cancer Cell Binding
Veettil, K. T., & Jayaraman, N. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00487 · Cited by 2
Barlang, L.-A., Mohl, B.-P., Blaurock, C., Harder, S., Breithaupt, A., Merkel, O. M., Balkema‐Buschmann, A., & Popp, A. (2023) · Acta Histochemica · doi:10.1016/j.acthis.2023.152077 · Cited by 2
Sour Consequences of Aberrant Glycosylation in Cancer Development
Festari, M. F., da Costa, V., García, I., Cedrés, M. E., & Freire, T. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_371 · Cited by 1
Sintusen, P., Vaeteewoottacharn, K., Cha’on, U., Pairojkul, C., Aphivatanasiri, C., Suttiprapa, S., Mahalapbutr, P., Silsirivanit, A., Wongkham, S., & Luang, S. (2025) · Scientific Reports · doi:10.1038/s41598-024-84444-7 · Cited by 1
Nano-conjugated drug delivery systems for enhanced tumour-specific targeting
Hirpara, M., Ahlawat, P., Patel, A., Patel, S., & Panjwani, D. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2587646 · Cited by 1
“Consequently, STn is produced using a different pathway that involves ST6GalNAc-I (Ju et al. 2014).”
Starost, K. A., Bommi, J. R., Mitra, P., & Field, S. J. (2026) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-032-16833-7_15 · Cited by 1
Chiale, C., Bay, S., Ganneau, C., & Freire, T. (2026) · Innate Immunity · doi:10.1177/17534259261449674 · Cited by 1
“9 – 11 The Tn antigen is overexpressed in various epithelial cancers, including breast, colon, and pancreatic carcinomas, and correlates with tumor progression, metastasis, and poor prognosis.”
Cosmc loss induces truncated O-glycosylation and accelerates Kras-driven pancreatic carcinogenesis
Mercanoglu, B., Schraps, N., Giannou, A. D., Zhou, J., Kind, S., Reinecke, M., Karstens, K.-F., Dreyer, B., Harder, S., Zhang, S., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101347 · Cited by 2
“COSMC loss provides a genetically defined mechanism to induce persistent O-glycan truncation and Tn-dominant glycosylation [11,14, 17,18].”
Arend, P. (2020) · Preprints.org · doi:10.20944/preprints202005.0321.v1
“This elongation is controlled by the synthesis of Galβ1-3GalNAcα1-O-Ser/Thr or T antigen [30] and is completed through ABO allelic O-glycosylation.”
BackgroundArend, P. (2021) · Preprints.org · doi:10.20944/preprints202005.0321.v2
“This elongation is controlled by the synthesis of Galβ1-3GalNAcα1-O-Ser/Thr or T antigen [34] and is completed through ABO allelic O-glycosylation.”
BackgroundRanjbary, A. G., Mehrzad, J., Abdollahi, A., Hosseinkhani, S., Tabatabaee, A., & Dehghani, H. (2019) · Research Square · doi:10.21203/rs.2.14756/v2 · Cited by 1
Mucins: Structure and Function
Salinas-Marín, R., Villanueva-Cabello, T. M., & Martínez-Duncker, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00082-1 · Cited by 1
Mehrzad, J., Ranjbary, A. G., Abdollahi, A., Hosseinkhani, S., Tabatabaee, A., & Dehghani, H. (2019) · Research Square · doi:10.21203/rs.2.14756/v1
“Polypeptide N acetylgalactosaminyl transferase (ppGalNAc-T) has been found to be a biomarker and prognostic indicator for breast, gastric and ovarian cancers [44, 45].”
Background(2014) · Cancer Biomarkers · doi:10.3233/cbm-2014-14614
Erger, F., Aryal, R. P., Reusch, B., Matsumoto, Y., Meyer, R., Zeng, J., Knopp, C., Noël, M., Wenzel, A., Kohl, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1716400/v1
Self-citationCD301b lectin expression in the breast tumor microenvironment augments tumor growthPreprint
Ozdilek, A., Paschall, A. V., Nawaz, Z., Niyas, A. M. M., & Avci, F. Y. (2024) · Research Square · doi:10.1101/2024.03.13.584829
Highly Glycosylated Mucins and FUT8 in Ulcerative Colitis
Cantero-Recasens, G. (2024) · Trends in Glycoscience and Glycotechnology · doi:10.4052/tigg.2325.1e
Vital Functions of Glycans in the Biological Systems
Rani, R., Malik, P., Singh, R., Kumar, R., Patel, V. H., & Mukherjee, T. K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815322521125010004
Kalemoglu, E., & Caner, A. (2025) · Cancer Reports · doi:10.1002/cnr2.70259
Ren, N., Qu, X., Wang, Z., Zhang, X., Hu, H., & Bai, X. (2026) · Central European Journal of Immunology · doi:10.5114/ceji/205599 · Cited by 1
Synthetic lethality and DNA damage response targeting in cancer stem cells: a comprehensive review
Sayed, U., Abdulsahib, W. K., Jasim, I. K., Malathi, H., Nayak, P. P., Anand, D. A., Mukherjee, G., Sinha, A., & Eshkaraev, S. C. (2026) · Discover Oncology · doi:10.1007/s12672-026-04587-z · Cited by 2
Tumor glycosylation engages CD301b-mediated myeloid regulation in breast cancerPreprint
Ozdilek, A., Paschall, A. V., Nawaz, F. Z., Niyas, A. M. M., & Avci, F. Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9347231/v1
“Cosmc is a chaperone essential in elongating the core O-glycan beyond the truncated Tn form of α-GalNAc 20,21,40 .”
Lectin based nanocarriers for drug delivery
Kaptan, E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33639-3.00005-2
Marseglia, A., Tito, G., Ferraro, G., Molinaro, A., Tame, J. R. H., Kamata, K., Merlino, A., & Marchetti, R. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153685
Protein O‐Glycosylation Shapes Lymphatic Endothelia and Lymph Node Macrophage Populations
Frey, J., Ratter, A., Brigger, F., Cielen, L., Kunz, P., Tulin, E. K. C., Mikos, K., Dieterich, L. C., D’Addio, M., Halin, C., et al. (2026) · The FASEB Journal · doi:10.1096/fj.202600240r
Self-citationBennion, R., Lohmann, E., Rio, G. D., Rouyer, L., Amrani, S. E., Kowalczewska, M., Guezennec, X. L., Mas, E., Dusetti, N., Chauvin, A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.04.749345
Zhang, J., Huang, L., Lyu, Z., Liu, Y., Qi, R., Hu, B., Long, S., Lu, Z., Shi, X., Cheng, B., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c13140
Metadata
- Authors
- Ju, T., Aryal, R. P., Kudelka, M. R., Wang, Y., & Cummings, R. D.
- Affiliations
- Emory University (US)
- Corresponding author
- Cummings, Richard D.
- Venue
- Cancer Biomarkers
- Publisher
- SAGE Publications
- Published
- 2014-02-27
- Volume
- 14
- Issue
- 1
- Pages
- 63-81
- ISSN
- 1574-0153 (ISSN-L)
- 1875-8592
- PMC
- PMC5808877
- OpenAlex
- W1544375765
- Cited by
- 153
- References
- 202
- Citations by year
- 2026: 11 · 2025: 13 · 2024: 11 · 2023: 22 · 2022: 14 · 2021: 14 · 2020: 18 · 2019: 14 · 2018: 10 · 2017: 5 · 2016: 11 · 2015: 7 · 2014: 2
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- Locations
- Cancer Biomarkers (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (U01CA168930)
- National Institute of General Medical Sciences (T32GM008169, R24GM098791)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Health Sciences › Medicine › Hematology › Blood groups and transfusion
- Keywords
- Tn antigen, sialyl-Tn antigen, Cosmc, T-synthase, O-glycosylation, tumor-associated carbohydrate antigens, X chromosome, molecular chaperones, protein misfolding, epigenetic regulation
- MeSH terms
- Animals, Carbohydrate Sequence, Glycosylation, Humans, Neoplasms, Polysaccharides, Antigens, Tumor-Associated, Carbohydrate, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.